World’s First COVID-19 Drug Based on Human Immunoglobulin Developed from Plasma of Recovered Patients
|
By HospiMedica International staff writers Posted on 14 Sep 2021 |
|
Illustration
The world’s first drug based on human immunoglobulin being developed from plasma of recovered patients could be effective on COVID-19 patients with mild conditions.
China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China) is developing two medicines for the treatment of COVID-19 based on human immunoglobulin and monoclonal antibody. Both the drugs could reduce the impact of the novel coronavirus in infected people and will be effective on patients with mild COVID-19, according to a report by the Global Times.
The first drug being developed from plasma of recovered COVID-19 patients or vaccinated uninfected people contains high-potency SARS-COV-2 neutralizing antibodies. The drug has demonstrated significant relief of symptoms and damage caused by SARS-COV-2 in pre-clinical studies and animal tests. The new drug containing a high level of neutralizing antibodies to the novel coronavirus is all set to soon enter Phase 3 clinical trials.
The second COVID-19 drug under development is based on a potent monoclonal antibody against the Delta variant discovered by researchers at Sinopharm. The monoclonal antibody is capable of effectively blocking the binding of the novel coronavirus to the Angiotensin-converting enzyme 2 which is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. According to Sinopharm, the antibody can prevent the SARS-COV-2 virus from infecting human cells.
Related Links:
China National Pharmaceutical Group Co., Ltd.
China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China) is developing two medicines for the treatment of COVID-19 based on human immunoglobulin and monoclonal antibody. Both the drugs could reduce the impact of the novel coronavirus in infected people and will be effective on patients with mild COVID-19, according to a report by the Global Times.
The first drug being developed from plasma of recovered COVID-19 patients or vaccinated uninfected people contains high-potency SARS-COV-2 neutralizing antibodies. The drug has demonstrated significant relief of symptoms and damage caused by SARS-COV-2 in pre-clinical studies and animal tests. The new drug containing a high level of neutralizing antibodies to the novel coronavirus is all set to soon enter Phase 3 clinical trials.
The second COVID-19 drug under development is based on a potent monoclonal antibody against the Delta variant discovered by researchers at Sinopharm. The monoclonal antibody is capable of effectively blocking the binding of the novel coronavirus to the Angiotensin-converting enzyme 2 which is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. According to Sinopharm, the antibody can prevent the SARS-COV-2 virus from infecting human cells.
Related Links:
China National Pharmaceutical Group Co., Ltd.
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Ureteral Dilatation Balloon
Dornier Equinox
Hemostatic Agent
HEMOBLAST Bellows
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
AI Model Identifies AF Patients Requiring Blood Thinners to Prevent Stroke
Atrial fibrillation (AF) is the most common abnormal heart rhythm, affecting around 59 million people globally. It increases stroke risk because quivering in the upper heart chambers allows blood clots... Read more
Soft Robot Intubation Device Could Save Lives
Maintaining an open airway is one of the most critical priorities in emergency medicine, as without oxygen flow, other interventions can quickly fail. Endotracheal intubation is the gold standard but remains... Read more
Surgical Techniques
view channel
Novel Method Uses Interstitial Fluid Flow to Predict Where Brain Tumor Can Grow Next
Glioblastoma is one of the most aggressive brain cancers, with patients surviving on average only 15 months after diagnosis. Surgery and radiation can temporarily control the tumor, but the disease almost... Read more
World’s First Custom Anterior Cervical Spine Surgery Performed Using Personalized Implant
Anterior cervical fusion has been performed since the 1950s and is one of the most common spine procedures. Traditional implants are designed as one-size-fits-all, which can affect spinal alignment, healing,... Read more
Patient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read more
Business
view channel
Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
B. Braun Acquires Digital Microsurgery Company True Digital Surgery
The high-end microsurgery market in neurosurgery, spine, and ENT is undergoing a significant transformation. Traditional analog microscopes are giving way to digital exoscopes, which provide improved visualization,... Read more
CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is scheduled to be held from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou.... Read more